You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

LOPINAVIR AND RITONAVIR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lopinavir And Ritonavir, and when can generic versions of Lopinavir And Ritonavir launch?

Lopinavir And Ritonavir is a drug marketed by Lannett Co Inc, Hetero Labs Ltd Iii, Laurus, and Mylan Labs Ltd. and is included in four NDAs.

The generic ingredient in LOPINAVIR AND RITONAVIR is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lopinavir And Ritonavir

A generic version of LOPINAVIR AND RITONAVIR was approved as lopinavir; ritonavir by LANNETT CO INC on December 27th, 2016.

  Try a Trial

US Patents and Regulatory Information for LOPINAVIR AND RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lannett Co Inc LOPINAVIR AND RITONAVIR lopinavir; ritonavir SOLUTION;ORAL 207407-001 Dec 27, 2016 AA RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Mylan Labs Ltd LOPINAVIR AND RITONAVIR lopinavir; ritonavir TABLET;ORAL 079074-002 Feb 7, 2024 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Laurus LOPINAVIR AND RITONAVIR lopinavir; ritonavir TABLET;ORAL 213857-001 Mar 21, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for LOPINAVIR AND RITONAVIR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Mylan Pharmaceuticals Limited Lopinavir/Ritonavir Mylan lopinavir, ritonavir EMEA/H/C/004025
Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Authorised yes no no 2016-01-14
AbbVie Deutschland GmbH Co. KG Kaletra lopinavir, ritonavir EMEA/H/C/000368
Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Authorised no no no 2001-03-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.